Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

ECHO-COPD: Impact of a Pharmacist-Led Health Belief Model-Based Educational Intervention Among COPD Patients (ECHO-COPD)

7. september 2026 opdateret af: Rabia Hussain

Impact of a Pharmacist-Led Health Belief Model-Based Educational Intervention on Medication Adherence, Quality of Life, and Direct Cost Among COPD Patients at Buraidah Central Hospital in Al-Qassim Region, Saudi Arabia: A Quasi-Experimental Design

Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease associated with substantial morbidity and mortality, impaired quality of life, and healthcare costs. Medication adherence and appropriate self-management are important components of COPD management; however, patients' health beliefs and perceptions may influence their adherence to treatment and engagement in recommended health behaviours. This study aims to evaluate the impact of a pharmacist-led educational intervention based on the Health Belief Model (HBM) on medication adherence, quality of life, and direct healthcare costs among patients with COPD receiving care at Buraidah Central Hospital (BCH) in Al-Qassim Region, Saudi Arabia.

A quantitative, quasi-experimental pretest-posttest control-group design will be used. Eligible COPD patients will be non-randomly assigned to either an intervention group or a control group. The intervention group will receive structured, pharmacist-led HBM-based educational sessions in addition to routine care. In contrast, the control group will continue to receive standard care without additional educational input. Baseline assessments will include medication adherence using the 8-item Morisky Medication Adherence Scale (MMAS-8); quality of life and health status using the COPD Assessment Test (CAT); health beliefs using a structured HBM questionnaire; and direct medical costs obtained from the hospital clinical cost centre. The educational intervention will be delivered over six months, followed by post-intervention assessment using the same outcome measures.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

The HBM will guide the content and delivery of the pharmacist-led educational intervention. The intervention will address the six core constructs of the HBM:

  1. Perceived susceptibility
  2. Perceived severity
  3. Perceived benefits
  4. Perceived barriers
  5. Cues to action
  6. Self-efficacy The purpose of applying the HBM is to influence patients' understanding of COPD and promote positive behavioural changes, particularly improvements in medication adherence. The study will then examine the relationship between these improvements and quality of life, healthcare utilisation, and direct healthcare costs.

The intervention will consist of structured face-to-face educational sessions conducted in the designated counselling room of the Pulmonary Department at BCH. Sessions will incorporate printed educational materials, lectures, counselling, practical demonstrations, motivational support, problem-solving strategies, and reinforcement of behavioural changes.

The educational programme will cover aspects of COPD management, medication adherence and appropriate medication use, COPD risk factors and complications, nutrition and preventive care, smoking cessation, barriers to recommended behaviours, cues to action, and strategies to improve patients' confidence in managing COPD.

Participants in the intervention and control groups will undergo pre-intervention assessments. Participants in the intervention group will subsequently receive the structured educational programme, while the control group will continue to receive standard care without additional educational input. Post-intervention assessments will use the same measurement instruments to allow within-group and between-group comparisons.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

140

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

  • Saudi Arabien
    • Al-Qassim Region
      • Buraidah, Al-Qassim Region, Saudi Arabien, 52391
        • Bander S Alshammeri
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Inclusion Criteria:

Participants must:

  1. Be adults aged 18-65 years.
  2. Be diagnosed with COPD stages I-III according to GOLD guidelines.
  3. Have visited or been admitted for a COPD exacerbation and be receiving care at BCH in Al-Qassim Region, Saudi Arabia.
  4. Be Arabic-speaking and capable of understanding study instructions.
  5. Be willing and able to provide written informed consent.

Exclusion Criteria:

Participants will be excluded if they:

  1. Are diagnosed with COPD stage IV.

  2. Have another significant pulmonary disease, including:

    • Asthma
    • Bronchiectasis
    • Pneumonia
    • Cystic fibrosis

  3. Have a serious systemic illness, severe comorbidity, or central organ dysfunction, including:

    • Hepatic dysfunction
    • Renal dysfunction
    • Psychiatric impairment
    • Sensory impairment
  4. Are immunocompromised or receiving immunosuppressive treatment.
  5. Have psychological, sensory, or cognitive impairment that prevents meaningful participation in the study.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Sundhedstjenesteforskning
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: HBM-Based Educational Intervention

Participants in the intervention group will receive routine care together with structured pharmacist-led educational sessions based on the HBM.

The educational intervention will be conducted face-to-face during scheduled outpatient appointments in the designated counselling room of the Pulmonary Department.

The programme will be delivered from study months 4 to 9.

Educational sessions will include:

  • Printed educational materials
  • Lectures
  • Individual counselling
  • Practical demonstrations
  • Personalised feedback
  • Problem-solving strategies
  • Motivational support
  • Interactive activities
  • Peer group discussions
  • Reinforcement of behavioural changes The six HBM constructs will guide the educational content.
Adfærdsmæssigt: Pharmacist-Led HBM-Based Educational Intervention

Participants in the intervention group will receive routine care together with structured pharmacist-led educational sessions based on the HBM.

The educational intervention will be conducted face-to-face during scheduled outpatient appointments in the designated counselling room of the Pulmonary Department.

The programme will be delivered from study months 4 to 9.

Educational sessions will include:

  • Printed educational materials
  • Lectures
  • Individual counselling
  • Practical demonstrations
  • Personalised feedback
  • Problem-solving strategies
  • Motivational support
  • Interactive activities
  • Peer group discussions
  • Reinforcement of behavioural changes The six HBM constructs will guide the educational content.
Ingen indgriben: Standard Care

Participants in the control group will continue to receive routine/standard care provided by BCH.

They will not receive the additional structured pharmacist-led HBM-based educational intervention.

Both intervention and control participants will undergo the same baseline and post-intervention assessments.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Medication Adherence
Tidsramme: Baseline and 6 months after initiation of the educational intervention.
Change in medication adherence Measurement Tool 8-item Morisky Medication Adherence Scale (MMAS-8), prevalidated Arabic version Medication adherence will be assessed using MMAS-8 at baseline and following completion of the intervention.
Baseline and 6 months after initiation of the educational intervention.

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Quality of Life and Health Status
Tidsramme: Baseline and 6 months after initiation of the educational intervention.
Change in quality of life/health status Measurement Tool COPD Assessment Test (CAT), prevalidated Arabic version The CAT will be administered to participants in both groups at baseline and after completion of the intervention.
Baseline and 6 months after initiation of the educational intervention.
Direct Healthcare Costs
Tidsramme: Direct medical costs assessed during the pre-intervention baseline period and during the post-intervention follow-up period after completion of the six-month intervention.

Change in direct medical costs associated with COPD Direct medical cost data will be obtained from the clinical cost centre of BCH.

The costing analysis will include direct COPD-related healthcare resources such as:

  • Medications
  • Laboratory tests
  • Chest X-rays
  • Oxygen therapy Other direct medical resources documented within the approved data-collection instrument will be included as applicable.

Important Costing Specification The cost of delivering the educational intervention will not be included in the costing analysis.

The economic component of this study focuses on the direct cost of illness associated with COPD rather than the cost of implementing the educational intervention.
Direct medical costs assessed during the pre-intervention baseline period and during the post-intervention follow-up period after completion of the six-month intervention.

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
HBM Constructs
Tidsramme: Baseline and 6 months after initiation of the educational intervention.

Changes in patients' health beliefs will be assessed using a structured, prevalidated Arabic HBM questionnaire.

The questionnaire assesses:

  • Perceived susceptibility
  • Perceived severity
  • Perceived benefits
  • Perceived barriers
  • Cues to action
  • Self-efficacy
Baseline and 6 months after initiation of the educational intervention.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Rabia Hussain

Samarbejdspartnere

Universiti Sains Malaysia

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. september 2026

Primær færdiggørelse (Anslået)

30. august 2027

Studieafslutning (Anslået)

31. august 2027

Datoer for studieregistrering

Først indsendt

7. september 2026

Først indsendt, der opfyldte QC-kriterier

7. september 2026

Først opslået (Faktiske)

11. september 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

11. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

7. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • USM-DSAP-2026-002

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner